NEW YORK,  March 12 – DoubleTwist CEO John Couch said Monday that the company’s withdrawal of its IPO last week was nothing but “a tactical financial move,” noting that the company has enough cash to last through the year.

While leaving open the possibility of raising money through a private placement or a merger, Couch said he would focus on boosting the company’s revenues from subscriptions to its annotated databases of genomic data and associated bioinformatics tools. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.